Welcome to our dedicated page for Fosun Internatio news (Ticker: FOSUY), a resource for investors and traders seeking the latest updates and insights on Fosun Internatio stock.
News about Fosun International Limited (FOSUY) covers a broad range of topics reflecting its activities as a global innovation-driven consumer group. Company announcements and media releases describe developments across pharmaceuticals and healthcare, cultural tourism and consumption, financial services, and insurance, as well as updates on its innovation and globalization strategy.
Investors and observers can find news on Fosun’s pharmaceutical and healthcare initiatives, including progress in innovative drugs, medical devices, and healthcare services under entities such as Fosun Pharma and Henlius. Releases highlight clinical and regulatory milestones, new therapeutic indications, and the use of artificial intelligence in areas such as drug development decision-making and clinical trial prediction.
Coverage also includes cultural tourism and consumption news, such as performance and expansion of Club Med resorts under Fosun Tourism Group, cultural events, and consumer-focused projects. In financial services and insurance, news items discuss developments at Fosun Insurance Portugal (Fidelidade), asset servicing activities in Europe, and strategic portfolio adjustments, including asset sales and retained businesses.
Another important theme in Fosun-related news is ESG and sustainability. Articles describe its ESG ratings, inclusion in sustainability indices and yearbooks, climate disclosure practices, and social responsibility programs such as the Rural Doctors Program and contributions to global malaria treatment. Governance and award recognitions, including honors from organizations like Corporate Governance Asia, also feature prominently.
For those following FOSUY, this news stream provides insight into how Fosun advances its stated strategy of "Innovation + Globalization", how its core subsidiaries perform, and how it integrates ESG considerations into its operations. Regularly reviewing these updates can help readers understand the group’s evolving business focus and corporate priorities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Fosun has initiated a global campaign for a malaria-free world, aligning with World Malaria Day on April 25. The campaign involved various charitable activities in over 15 countries from April 20 to April 26, emphasizing investment and innovation.
Fosun Pharma, leveraging over 30 years of expertise, has distributed over 280 million artesunate injections, saving over 56 million lives, primarily in Africa. The company launched a production facility in Ivory Coast in November 2022 to enhance local pharmaceutical access, which is expected to produce one billion tablets by 2024.
A charity song performed at a Premier League match further promoted the campaign, and Fosun's landmarks globally illuminated messages supporting malaria eradication. The company also aims to establish long-term charitable mechanisms in Africa, collaborating with various organizations to combat malaria effectively.
Fosun International reported a revenue of RMB 175.39 billion for 2022, an 8.7% increase despite challenges from the pandemic and international market volatility, with a net profit of RMB 0.54 billion. The company emphasized recovery in 2023, particularly in tourism and commercial sectors, and expressed confidence in future growth. Fosun divested non-core assets to streamline operations and focused on core business strengths. Notably, it received an MSCI ESG rating of AA and maintained stable debt ratios. The company aims to enhance product competitiveness through innovation and global operations while continuing to prioritize ESG responsibilities.
Fosun International announced its 2022 annual results, highlighting a total revenue of RMB175.39 billion, up 8.7% year-on-year. Overseas revenue reached RMB77.4 billion, representing a 14% increase and making up 44% of total revenue. The company invested RMB10.4 billion in R&D, marking a 17% rise. However, net profit was RMB0.54 billion, a sharp decline from RMB10.08 billion in 2021 due to high business costs and market downturns. Fosun has focused on divesting non-core assets, generating cash inflows of nearly RMB30 billion to stabilize operations. As of January 2023, they secured a RMB12 billion syndicated loan.